GSMA
9.2.2020 19:05:05 CET | Business Wire | Press release
The GSMA knows that the Coronavirus has created disruption, in particular for exhibitors and attendees from around the world, including the 5-6,000 (5-6%) who have historically attended from China. Our sympathy goes to all those affected. We are grateful for the preventative measures our Chinese exhibitors have put in place, notably ZTE and Huawei. Today, the GSMA is moving ahead as planned and will host MWC Barcelona 24-27 February 2020. While the GSMA confirm some large exhibitors have decided not to come to the show this year with others still contemplating next steps, we remain more than 2,800 exhibitors strong.
In addition to all of the health and safety measures put in place, the Spanish health authorities, Host City Partners, other relevant agencies and the GSMA are collaborating. The GSMA is seeking to reassure attendees and exhibitors that their health and safety are our paramount concern, by the following additional measures being put in place:
- All travellers from the Hubei province will not be permitted access to the event*
- All travellers who have been in China will need to demonstrate proof they have been outside of China 14 days prior to the event (passport stamp, health certificate)
- Temperature screening will be implemented
- Attendees will need to self-certify they have not been in contact with anyone infected.
While further planning is underway, we will continue to monitor the situation and will adapt our plans according to developments and advice we receive. We are contending with a constantly evolving situation, that will require fast adaptability.
Measures being implemented include:
- Increased cleaning and disinfection programme across all high-volume touchpoints, e.g. catering areas, surfaces, handrails, WCs, entrances/exits, public touch-screens, etc. along with the use of correct cleaning/sanitising materials and products
- Increased onsite medical support – doubled over last year
- Awareness campaign via online and onsite info-share and signage
- Availability of sanitising and disinfection materials for public use
- Awareness and training to all staff on standard personal preventative measures, e.g. personal hygiene, frequency of use of sanitising/disinfection products, etc.
- Advice to exhibitors on implementing effective cleaning and disinfection of stands, offices along with guidance on personal hygiene measures and common preventive behaviour
- Public health guidelines and advice communication to Barcelona hotels, public and private transport, restaurants and catering outlets, retail, etc.
- Installing new signage onsite reminding attendees of hygiene recommendations
- Implementing a microphone disinfecting and change protocol for all speakers
- Communicating advice to all attendees to adopt a ‘no-handshake policy’
- A 24-hour telephone Security and Medical service for all attendees, operational from 12th to 29th February 2020. This number appears on the back of badge holders, in the event App and on signage around the venue.
We understand that in a press conference on Friday 7 February Health Minister Alba Vergés explained that the region of Catalonia is not a public health risk zone. The Health Minister stated “The Catalan health system is prepared to detect and treat coronavirus, to give the most appropriate response, and this must be clear to those attending MWC Barcelona,” said Vergés.
In a similar vein, the Secretary of Public Health, Joan Guix, noted that Catalonia is used to continually welcoming thousands of visitors to the region and reiterated his confidence in the regions readiness and responsiveness. Guix outlined the measures that the Public Health Agency of Catalonia had put in place and that the Spanish Ministry of Health was in constant communication with all relevant bodies. These include the Directorate General of Tourism and Hotels, both public and private health centres, the Chinese consulate and with the GSMA.
Finally, the head of the Service of Preventive Medicine and Epidemiology of the Hospital Clínic de Barcelona, Antoni Trilla, emphasised that “we are not in an exceptional situation and our health system is ready”. The press release can be found here: https://govern.cat/salapremsa/notes-premsa/382568/verges-catalonia-is-prepared-to-detect-and-treat-novel-coronavirus
The GSMA strongly urges exhibitors and attendees to implement appropriate guidelines and protocols as suggested by the WHO and other health authorities to contain and mitigate against any further spread of the virus. The health and safety of our exhibitors, attendees and staff are of paramount importance.
Further updates from the GSMA, answers to the most frequently asked questions and an outline of the measures that have been implemented, are on our website and can be found on www.mwcbarcelona.com .
-ENDS-
Notes to Editors
*By event we mean that to cover MWC Barcelona, Four Years From Now (4YFN), xside and YoMo
Up-to-date WHO advice can be found here: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance and the most recent press release issued by WHO is here: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov) .
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Shanghai and Los Angeles, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200209005026/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
